Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
- Conditions
- Cerebral Small Vessel DiseasesStroke, Ischemic
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Christina Kruuse
- Target Recruit Count
- 100
- Registration Number
- NCT05173896
- Locations
- 🇩🇰
Department of Neurology, Herlev Gentofte Hospital, Herlev, Denmark
🇩🇰Danish Research Centre for Magnetic Resonance, Hvidovre, Denmark
Impact of Tadalafil 5 mg on Post-micturition Dribble in Young-age Men With no/Mild Lower Urinary Tract Symptoms
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 80
- Registration Number
- NCT05146674
- Locations
- 🇪🇬
Mansoura Urology and Nephrology Center, Mansoura, DK, Egypt
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
- Conditions
- Priapism Due to Sickle Cell Disease
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT05142254
- Locations
- 🇳🇬
Murtala Mohammed Specialist Hospital, Kano, Nigeria
🇳🇬Aminu Kano Teaching Hospital, Kano, Nigeria
Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Ankara Training and Research Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05109377
- Locations
- 🇹🇷
Veysel Bayburtluoğlu, Ankara, Turkey
Effects of Single Dose Tadalafil on Urethral and Anal Closure Function
- Conditions
- Fecal IncontinenceUrinary Incontinence,Stress
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- University Hospital Bispebjerg and Frederiksberg
- Target Recruit Count
- 24
- Registration Number
- NCT05095077
- Locations
- 🇩🇰
Zelo Phase 1 unit, Copenhagen, Denmark
Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation
- Conditions
- Erectile DysfunctionPremature Ejaculation
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- EMS
- Target Recruit Count
- 232
- Registration Number
- NCT05052879
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
- Conditions
- Pre-diabetesObesity
- Interventions
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Philip Kern
- Target Recruit Count
- 96
- Registration Number
- NCT05051436
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction
- Conditions
- Erectile Dysfunction
- Interventions
- Procedure: Li-ESWT
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Dr. Soetomo General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05043896
- Locations
- 🇮🇩
dr. Soetomo General Hospital, Surabaya, Jawa Timur, Indonesia
The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 100
- Registration Number
- NCT05030623
- Locations
- 🇪🇬
Faculty of Pharmacy, Shibīn Al Kawm, Menoufia, Egypt
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-04-16
- Target Recruit Count
- 17
- Registration Number
- NCT05014776
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.